Atossa Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 34.44 million compared to USD 26.96 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 USD | +1.94% |
|
-6.25% | +19.32% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.32% | 132M | |
+23.13% | 46.93B | |
+37.49% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023